A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
EF Smit, E Fokkema, B Biesma, HJM Groen… - British journal of …, 1998 - nature.com
The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
[引用][C] A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
EF SMIT, E FOKKEMA, B BIESMA… - British journal of …, 1998 - pascal-francis.inist.fr
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.
EF Smit, E Fokkema, B Biesma, HJ Groen… - British Journal of …, 1998 - europepmc.org
The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
[PDF][PDF] A phase 11 study of paclitaxel in heavily pretreated patients with small-cell lung cancer
EF Smit, E Fokkema, B Biesma, HJM Groen… - British Journal of …, 1998 - academia.edu
Thepurpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
EF Smit, E Fokkema, B Biesma, HJM Groen… - British Jounal of …, 1998 - research.rug.nl
The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
EF Smit, E Fokkema, B Biesma… - British journal of …, 1998 - pubmed.ncbi.nlm.nih.gov
The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
[PDF][PDF] A phase 11 study of paclitaxel in heavily pretreated patients with small-cell lung cancer
EF Smit, E Fokkema, B Biesma, HJM Groen… - British Journal of …, 1998 - researchgate.net
Thepurpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.
EF Smit, E Fokkema, B Biesma, HJ Groen… - British Journal of …, 1998 - ncbi.nlm.nih.gov
The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
[引用][C] A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
S EF - Br J Cancer, 1998 - cir.nii.ac.jp
[PDF][PDF] A phase 11 study of paclitaxel in heavily pretreated patients with small-cell lung cancer
EF Smit, E Fokkema, B Biesma, HJM Groen… - British Journal of …, 1998 - Citeseer
Thepurpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with …